Patient eligibility
cancers, autoimmune diseases, hemorrhage, syphilis, chronic disease or, effusion, gastrointestinal obstruction, hypokalemia
HEPATITIS B, CANCERS, VIRUS, HEART DISEASE, BRAIN METASTASES, AUTOIMMUNE DISEASES, HYPOMAGNESEMIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTION, HEMORRHAGE, MALIGNANCIES, SYPHILIS, HEPATITIS C, EFFUSION, ONCOLOGY, GASTROINTESTINAL OBSTRUCTION
Patients with pathologically confirmed advanced HER2‐positive (3+ or 2+ staining intensity by immunohistochemistry or gene amplification by fluorescence in situ hybridization amplification [HER2:CEP17 ratio ≥2]) GC who suffered previous standard treatments (without docetaxel or other anti‐HER2 TKIs) failure or intolerance were considered. Other key inclusion criteria were age 18–70 years, measurable lesions per RECIST V1.1, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate organ and bone marrow function, and a life expectancy of at least 3 months.Patients were excluded if they had a history of autoimmune diseases or requirement of long‐term use of steroids (≥50 days); brain metastases; symptomatic or uncontrolled third space effusion; unable to take the drugs orally; uncontrolled hypokalemia and hypomagnesemia; a history of other antitumor therapy within 4 weeks before or during study; active hemorrhage within 2 months before study; chronic disease or gastrointestinal obstruction effecting absorption; other malignancies (except for cured locally cancers) within 5 years before study entry; a history of active hepatitis B virus, hepatitis C virus, syphilis or human immunodeficiency virus infection; uncontrolled heart disease. Each patient provided written informed consent.